Sinohealth Technology Holdings (2361) H2 2024 earnings summary

Executive summary

• FY2024 revenue rose 1.9% YoY to RMB403.7m; net profit increased 10.8% to RMB111.8m, with gross margin up 1.4 percentage points to 57.8%.

• AI-led product upgrades supported improved operating efficiency, growth in innovative in-hospital business and expansion across healthcare, pharmacy, health management and R&D services.

Financial highlights

• Revenue was RMB403.728m, up 1.9% YoY; cost of sales fell 1.3% to RMB170.527m and gross profit rose 4.4% to RMB233.201m.

• Profit before tax increased 8.5% to RMB120.148m; net profit rose 10.8% to RMB111.823m, aided by lower impairment losses and income tax expense.

• R&D costs increased 6.0% to RMB64.771m; selling and distribution expenses rose 23.7% to RMB40.084m, and administrative expenses increased 11.1% to RMB38.5m.

• EPS was RMB0.2697, versus RMB0.2394 in FY2023; profit attributable to owners was RMB110.649m.

Outlook and guidance

• Priorities include scaling To B, accelerating To C product upgrades and monetization, developing To R biomedical R&D solutions, and expanding five AI agent applications.

• Planned AI investment includes broader healthcare data, multimodal models, expanded disease and drug coverage, and intelligent agents for medical, pharmacy, business, health management and R&D use cases.

• To C plans focus on wider health-management coverage and serious-illness platform upgrades; To R plans include R&D solutions and potential investment, M&A and partnerships in innovative drugs and devices.